Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD19-targeted CAR-γδT in R/R B-ALL
NCT06696833Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH10304-BAL-01 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
QH10304-BAL-01
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06696833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696833.